Synthesis of new indeno[1,2-e]pyrimido[4,5-b][1,4]diazepine-5,11-diones as potential antitumor agents. 2008

Braulio Insuasty, and Fabian Orozco, and Carolina Lizarazo, and Jairo Quiroga, and Rodrigo Abonia, and Mike Hursthouse, and Manuel Nogueras, and Justo Cobo
Heterocyclic Compounds Research Group, Department of Chemistry, Universidad del Valle, A.A. 25360 Cali, Colombia. brainsu@univalle.edu.co

Novel racemic indeno[1,2-e]pyrimido[4,5-b][1,4]diazepine-5,11-diones 3-29 were obtained regioselectivily from the reaction of 5,6-diamino-3,4-dihydropyrimidin-4-ones 1 and 2-arylideneindandiones 2 as reagents. These compounds have been evaluated at the US National Cancer Institute (NCI) for their ability to inhibit approximately 60 different human tumor cell lines, where 5 and 6 presented remarkable activity against 57 and 48 cancer cell lines, respectively, with the most important GI(50) values ranging from 0.49 to 1.46 microM, in vitro assay.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D011744 Pyrimidinones Heterocyclic compounds known as 2-pyrimidones (or 2-hydroxypyrimidines) and 4-pyrimidones (or 4-hydroxypyrimidines) with the general formula C4H4N2O. Pyrimidinone,Pyrimidone,Pyrimidones
D003984 Dibenzazepines Compounds with two BENZENE rings fused to AZEPINES.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001381 Azepines Seven membered heterocyclic rings containing a NITROGEN atom. Hexamethyleneimines
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D020128 Inhibitory Concentration 50 The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture. IC50,Concentration 50, Inhibitory

Related Publications

Braulio Insuasty, and Fabian Orozco, and Carolina Lizarazo, and Jairo Quiroga, and Rodrigo Abonia, and Mike Hursthouse, and Manuel Nogueras, and Justo Cobo
October 2018, European journal of medicinal chemistry,
Braulio Insuasty, and Fabian Orozco, and Carolina Lizarazo, and Jairo Quiroga, and Rodrigo Abonia, and Mike Hursthouse, and Manuel Nogueras, and Justo Cobo
July 2010, European journal of medicinal chemistry,
Braulio Insuasty, and Fabian Orozco, and Carolina Lizarazo, and Jairo Quiroga, and Rodrigo Abonia, and Mike Hursthouse, and Manuel Nogueras, and Justo Cobo
March 2015, European journal of medicinal chemistry,
Braulio Insuasty, and Fabian Orozco, and Carolina Lizarazo, and Jairo Quiroga, and Rodrigo Abonia, and Mike Hursthouse, and Manuel Nogueras, and Justo Cobo
January 2014, Beilstein journal of organic chemistry,
Braulio Insuasty, and Fabian Orozco, and Carolina Lizarazo, and Jairo Quiroga, and Rodrigo Abonia, and Mike Hursthouse, and Manuel Nogueras, and Justo Cobo
April 2011, Bioorganic & medicinal chemistry letters,
Braulio Insuasty, and Fabian Orozco, and Carolina Lizarazo, and Jairo Quiroga, and Rodrigo Abonia, and Mike Hursthouse, and Manuel Nogueras, and Justo Cobo
September 2012, Archiv der Pharmazie,
Braulio Insuasty, and Fabian Orozco, and Carolina Lizarazo, and Jairo Quiroga, and Rodrigo Abonia, and Mike Hursthouse, and Manuel Nogueras, and Justo Cobo
April 2006, Bioorganic & medicinal chemistry letters,
Braulio Insuasty, and Fabian Orozco, and Carolina Lizarazo, and Jairo Quiroga, and Rodrigo Abonia, and Mike Hursthouse, and Manuel Nogueras, and Justo Cobo
November 2017, European journal of medicinal chemistry,
Braulio Insuasty, and Fabian Orozco, and Carolina Lizarazo, and Jairo Quiroga, and Rodrigo Abonia, and Mike Hursthouse, and Manuel Nogueras, and Justo Cobo
November 2023, Chemical biology & drug design,
Braulio Insuasty, and Fabian Orozco, and Carolina Lizarazo, and Jairo Quiroga, and Rodrigo Abonia, and Mike Hursthouse, and Manuel Nogueras, and Justo Cobo
February 1969, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
Copied contents to your clipboard!